Literature DB >> 24943712

Incidence and survival for Merkel cell carcinoma in Queensland, Australia, 1993-2010.

Danny R Youlden1, H Peter Soyer2, Philippa H Youl1, Lin Fritschi3, Peter D Baade1.   

Abstract

IMPORTANCE: Merkel cell carcinoma (MCC) is an uncommon but highly invasive form of skin cancer. The mechanisms that cause MCC are yet to be fully determined.
OBJECTIVES: To compare the incidence and survival rates of MCC in Queensland, Australia, known to be a high-risk area, with MCC incidence and survival elsewhere in the world. We also analyzed incidence trends and differences in survival by key demographic and clinical characteristics. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of population-based administrative data for MCC collected by the Queensland Cancer Registry and supplemented with detailed histopathologic data. Deidentified records were obtained of all Queensland residents diagnosed as having MCC during the period from 1993 to 2010. A subsample of histopathologic records were reviewed by a senior dermatopathologist to determine the potential for misclassification. A total of 879 eligible cases of MCC were included in the study. MAIN OUTCOMES AND MEASURES: Incidence rates were directly age standardized to the 2000 United States Standard Population. Trends were examined using Joinpoint software with results expressed in terms of the annual percentage change. The period method was used to calculate 5-year relative survival, and adjusted hazard ratios were obtained from multivariate Poisson models.
RESULTS: There were 340 cases of MCC diagnosed in Queensland between 2006 and 2010, corresponding to an incidence rate of 1.6 per 100,000 population. Men (2.5 per 100,000) had higher incidence than women (0.9 per 100,000), and rates peaked at 20.7 per 100,000 for persons 80 years or older. The overall incidence of MCC increased by an average of 2.6% per year from 1993 onwards. Relative survival was 41% after 5 years, with significantly better survival found for those younger than 70 years at diagnosis (56%-60%), those with tumors on the face or ears (51%), and those with stage I lesions (49%). CONCLUSIONS AND RELEVANCE: Incidence rates for MCC in Queensland are at least double those of any that have been previously published elsewhere in the world. It is likely that Queensland's combination of a predominantly white population, outdoor lifestyle, and exposure to sunlight has played a role in this unwanted result. Interventions are required to increase awareness of MCC among clinicians and the public.

Entities:  

Mesh:

Year:  2014        PMID: 24943712     DOI: 10.1001/jamadermatol.2014.124

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  36 in total

Review 1.  Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Authors:  Rocio Garcia-Carbonero; Ivan Marquez-Rodas; Luis de la Cruz-Merino; Javier Martinez-Trufero; Miguel Angel Cabrera; Jose Maria Piulats; Jaume Capdevila; Enrique Grande; Salvador Martin-Algarra; Alfonso Berrocal
Journal:  Oncologist       Date:  2019-04-08

2.  The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC).

Authors:  Linde M van Veenendaal; Eduardo Bertolli; Catharina M Korse; W Martin C Klop; Margot E T Tesselaar; Alexander C J van Akkooi
Journal:  Ann Surg Oncol       Date:  2020-06-11       Impact factor: 5.344

3.  Multiple primary cancers associated with Merkel cell carcinoma in Queensland, Australia, 1982-2011.

Authors:  Danny R Youlden; Philippa H Youl; H Peter Soyer; Lin Fritschi; Peter D Baade
Journal:  J Invest Dermatol       Date:  2014-07-03       Impact factor: 8.551

4.  Gender Disparity and Mutation Burden in Metastatic Melanoma.

Authors:  Sameer Gupta; Mykyta Artomov; William Goggins; Mark Daly; Hensin Tsao
Journal:  J Natl Cancer Inst       Date:  2015-08-20       Impact factor: 13.506

Review 5.  A case series and literature review of Merkel cell carcinoma metastasizing to pancreas.

Authors:  Yezaz A Ghouri; Somashekar G Krishna; Uma R Kundu; Manoop S Bhutani; Manoop S Butani; Jeffrey H Lee; William A Ross
Journal:  Dig Dis Sci       Date:  2015-01-14       Impact factor: 3.199

Review 6.  Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.

Authors:  Teresa Amaral; Ulrike Leiter; Claus Garbe
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

7.  The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment.

Authors:  Andreas Stang; Jürgen C Becker; Paul Nghiem; Jacques Ferlay
Journal:  Eur J Cancer       Date:  2018-03-20       Impact factor: 9.162

8.  Left-sided laterality of Merkel cell carcinoma in a German population: more than just sun exposure.

Authors:  T Gambichler; U Wieland; S Silling; M Dreißigacker; J Schaller; H-J Schulze; F Oellig; A Kreuter; M Stücker; F G Bechara; E Stockfleth; J C Becker
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-24       Impact factor: 4.553

9.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

10.  Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma.

Authors:  R U Wahl; T Braunschweig; A Ghassemi; A Rübben
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.